Examkin

Question

Difficulty: HardSchizophrenia and Psychotic Disorders

A 32-year-old man with a recent diagnosis of schizophrenia is admitted to the inpatient psychiatric unit due to worsening paranoia and command auditory hallucinations. Due to severe agitation, he is treated with multiple doses of intramuscular haloperidol over a 48-hour period. On hospital day 3, the patient develops profound "lead-pipe" muscle rigidity, a temperature of 39.4°C (102.9°F), profuse diaphoresis, and mutism. His blood pressure fluctuates between 160/100 mmHg and 90/60 mmHg, and his pulse is 122/min. Laboratory testing reveals a serum creatine kinase level of 4,500 U/L.

Arrange the following steps in the most appropriate chronological order for the acute management and subsequent follow-up of this patient's condition.

  1. 1Discontinue all current dopamine receptor antagonist medications immediately.
  2. 2Initiate aggressive supportive care, including intravenous fluid resuscitation and external cooling.
  3. 3Administer targeted pharmacotherapy, such as bromocriptine or dantrolene, for symptoms failing to improve.
  4. 4Consider electroconvulsive therapy (ECT) for severe symptoms that are refractory to medical management.
  5. 5Wait a minimum of two weeks after complete symptom resolution before cautiously introducing a low-potency antipsychotic.

Answer

The correct sequence for managing neuroleptic malignant syndrome (NMS) is: 1) Discontinue the offending agent, 2) Initiate supportive care, 3) Administer targeted pharmacotherapy, 4) Consider ECT for refractory cases, and 5) Wait at least two weeks before cautiously re-challenging with an alternative antipsychotic.
The algorithm for managing Neuroleptic Malignant Syndrome (NMS) requires a strict stepwise approach to minimize mortality and morbidity. The very first step is to remove the offending cause by discontinuing all dopamine antagonists. Because NMS can cause severe dehydration, hyperthermia, and rhabdomyolysis leading to acute renal failure, aggressive supportive care (IV fluids, cooling blankets) is the immediate next priority. If the patient does not respond adequately to these foundational steps, specific medical therapies that reverse dopamine blockade (e.g., bromocriptine, amantadine) or act as direct muscle relaxants (e.g., dantrolene) are administered. In the most severe, treatment-refractory cases, or those presenting with profound catatonia, electroconvulsive therapy (ECT) is highly effective. Finally, for the long-term management of the patient's underlying schizophrenia, it is critical to wait at least two weeks after complete resolution of NMS symptoms before cautiously re-challenging with a different, usually lower-potency, antipsychotic to prevent a recurrence.

Step-by-Step Solution

1
Identify the clinical presentation as Neuroleptic Malignant Syndrome (NMS).
The patient's classic tetrad of altered mental status, autonomic instability, hyperthermia, and "lead-pipe" muscle rigidity, combined with recent high-dose haloperidol use and elevated creatine kinase, confirms the diagnosis of NMS.
Accurate diagnosis is required to initiate the specific, stepwise, life-saving management protocol.
2
Determine the first and most critical acute intervention.
The immediate discontinuation of all dopamine receptor antagonists (in this case, haloperidol) is the paramount first step.
Continued exposure to the offending agent will worsen the dopamine blockade driving the syndrome, rendering other treatments ineffective.
3
Sequence the subsequent acute stabilization interventions.
Aggressive supportive care (IV fluids, cooling) must be instituted next. If this fails, targeted pharmacotherapy (bromocriptine, dantrolene, amantadine) is added. If the patient remains refractory and severely ill, ECT is the definitive acute treatment.
Treatment escalates from least invasive/fundamental (supportive care) to targeted medical therapy, and finally to highly invasive procedures (ECT) based on clinical response.
4
Establish the long-term management strategy for the underlying psychosis.
After full recovery from NMS, a washout period of at least two weeks is mandatory before cautiously re-challenging the patient with a different antipsychotic (typically an atypical, lower-potency agent like quetiapine or clozapine).
Premature re-introduction of antipsychotics carries an unacceptably high risk of NMS recurrence.

Key Concept

Neuroleptic Malignant Syndrome (NMS) Stepwise Management Algorithm
Estimated Time:1m 30s
Rate this question

Topics

Schizophrenia and Psychotic Disorders

More questions from this topic